Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1997 Feb;150(2):393–400.

Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications.

P T Cagle 1, A K el-Naggar 1, H J Xu 1, S X Hu 1, W F Benedict 1
PMCID: PMC1858295  PMID: 9033254

Abstract

Neuroendocrine lung tumors have been considered by some to be a continuum ranging from relatively benign typical carcinoids to highly malignant small-cell carcinomas. Histopathological diagnosis may sometimes be difficult because of their overlapping features. Correct classification, however, carries important prognostic and therapeutic significance. To determine the clinicopathological implications of retinoblastoma (RB) protein expression in these neoplasms, we examined the RB status in a series of neuroendocrine tumors by immunohistochemical analysis of paraffin-embedded tissue sections. A total of 105 tumors were studied. All 44 typical and 15 atypical carcinoids, one of which was initially misdiagnosed as a small-cell carcinoma, manifested a heterogeneous RB-positive staining pattern. Atypical carcinoids in general showed an increase in the number of tumor cells with strong nuclear staining compared to typical carcinoids. In contrast, all 40 small-cell and 6 large-cell neuroendocrine carcinomas failed to show RB staining in any tumor nuclei, indicating loss of RB function. Our results suggest that RB status as measured by immunohistochemical staining can be used as a marker to distinguish typical and atypical carcinoids from small-cell and large-cell neuroendocrine carcinomas.

Full text

PDF
393

Images in this article

396Figure 1
on p.396

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiba T., Naruke T., Kondo H., Goya T., Tsuchiya R., Suemasu K., Noguchi M., Sakurai K. Carcinoid tumor of the lung: clinicopathological study of 32 cases. Jpn J Clin Oncol. 1992 Apr;22(2):92–95. [PubMed] [Google Scholar]
  2. Barbareschi M., Girlando S., Mauri F. A., Arrigoni G., Laurino L., Dalla Palma P., Doglioni C. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol. 1992 Apr;166(4):343–350. doi: 10.1002/path.1711660405. [DOI] [PubMed] [Google Scholar]
  3. Benedict W. F., Xu H. J., Hu S. X., Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest. 1990 Apr;85(4):988–993. doi: 10.1172/JCI114575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cance W. G., Brennan M. F., Dudas M. E., Huang C. M., Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med. 1990 Nov 22;323(21):1457–1462. doi: 10.1056/NEJM199011223232105. [DOI] [PubMed] [Google Scholar]
  5. Carter D., Yesner R. Carcinomas of the lung with neuroendocrine differentiation. Semin Diagn Pathol. 1985 Nov;2(4):235–254. [PubMed] [Google Scholar]
  6. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  7. Cattoretti G., Pileri S., Parravicini C., Becker M. H., Poggi S., Bifulco C., Key G., D'Amato L., Sabattini E., Feudale E. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol. 1993 Oct;171(2):83–98. doi: 10.1002/path.1711710205. [DOI] [PubMed] [Google Scholar]
  8. Cordon-Cardo C., Wartinger D., Petrylak D., Dalbagni G., Fair W. R., Fuks Z., Reuter V. E. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst. 1992 Aug 19;84(16):1251–1256. doi: 10.1093/jnci/84.16.1251. [DOI] [PubMed] [Google Scholar]
  9. Cryns V. L., Thor A., Xu H. J., Hu S. X., Wierman M. E., Vickery A. L., Jr, Benedict W. F., Arnold A. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 1994 Mar 17;330(11):757–761. doi: 10.1056/NEJM199403173301105. [DOI] [PubMed] [Google Scholar]
  10. Dodson M. K., Cliby W. A., Xu H. J., DeLacey K. A., Hu S. X., Keeney G. L., Li J., Podratz K. C., Jenkins R. B., Benedict W. F. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res. 1994 Feb 1;54(3):610–613. [PubMed] [Google Scholar]
  11. Francioni F., Rendina E. A., Venuta F., Pescarmona E., De Giacomo T., Ricci C. Low grade neuroendocrine tumors of the lung (bronchial carcinoids)--25 years experience. Eur J Cardiothorac Surg. 1990;4(9):472–476. doi: 10.1016/1010-7940(90)90168-y. [DOI] [PubMed] [Google Scholar]
  12. Geradts J., Hu S. X., Lincoln C. E., Benedict W. F., Xu H. J. Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. Int J Cancer. 1994 Jul 15;58(2):161–167. doi: 10.1002/ijc.2910580203. [DOI] [PubMed] [Google Scholar]
  13. Gould V. E., Linnoila R. I., Memoli V. A., Warren W. H. Neuroendocrine cells and neuroendocrine neoplasms of the lung. Pathol Annu. 1983;18(Pt 1):287–330. [PubMed] [Google Scholar]
  14. Gouyer V., Gazzeri S., Brambilla E., Bolon I., Moro D., Perron P., Benabid A. L., Brambilla C. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer. 1994 Sep 15;58(6):818–824. doi: 10.1002/ijc.2910580612. [DOI] [PubMed] [Google Scholar]
  15. Hammar S., Bockus D., Remington F., Cooper L. The unusual spectrum of neuroendocrine lung neoplasms. Ultrastruct Pathol. 1989 Sep-Dec;13(5-6):515–560. doi: 10.3109/01913128909074534. [DOI] [PubMed] [Google Scholar]
  16. Henson J. W., Schnitker B. L., Correa K. M., von Deimling A., Fassbender F., Xu H. J., Benedict W. F., Yandell D. W., Louis D. N. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol. 1994 Nov;36(5):714–721. doi: 10.1002/ana.410360505. [DOI] [PubMed] [Google Scholar]
  17. Hurr K., Kemp B., Silver S. A., el-Naggar A. K. Microsatellite alteration at chromosome 3p loci in neuroendocrine and non-neuroendocrine lung tumors. Histogenetic and clinical relevance. Am J Pathol. 1996 Aug;149(2):613–620. [PMC free article] [PubMed] [Google Scholar]
  18. Ishida T., Yokoyama H., Sugio K., Kaneko S., Sugimachi K., Hara N., Ohta M. Carcinoid tumor of the lung: clinicopathological and immunohistochemical studies. Eur J Surg Oncol. 1992 Apr;18(2):180–187. [PubMed] [Google Scholar]
  19. Kim T. M., Benedict W. F., Xu H. J., Hu S. X., Gosewehr J., Velicescu M., Yin E., Zheng J., D'Ablaing G., Dubeau L. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res. 1994 Feb 1;54(3):605–609. [PubMed] [Google Scholar]
  20. Kubota Y., Miyamoto H., Noguchi S., Shuin T., Kitamura H., Xu H. J., Hu S. X., Benedict W. F. The loss of retinoblastoma gene in association with c-myc and transforming growth factor-beta 1 gene expression in human bladder cancer. J Urol. 1995 Aug;154(2 Pt 1):371–374. doi: 10.1097/00005392-199508000-00009. [DOI] [PubMed] [Google Scholar]
  21. Lai S. L., Brauch H., Knutsen T., Johnson B. E., Nau M. M., Mitsudomi T., Tsai C. M., Whang-Peng J., Zbar B., Kaye F. J. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 1995 Mar-Apr;15(2):225–232. [PubMed] [Google Scholar]
  22. Logothetis C. J., Xu H. J., Ro J. Y., Hu S. X., Sahin A., Ordonez N., Benedict W. F. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst. 1992 Aug 19;84(16):1256–1261. doi: 10.1093/jnci/84.16.1256. [DOI] [PubMed] [Google Scholar]
  23. Pei L., Melmed S., Scheithauer B., Kovacs K., Benedict W. F., Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res. 1995 Apr 15;55(8):1613–1616. [PubMed] [Google Scholar]
  24. Przygodzki R. M., Finkelstein S. D., Langer J. C., Swalsky P. A., Fishback N., Bakker A., Guinee D. G., Koss M., Travis W. D. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol. 1996 May;148(5):1531–1541. [PMC free article] [PubMed] [Google Scholar]
  25. Travis W. D., Linnoila R. I., Tsokos M. G., Hitchcock C. L., Cutler G. B., Jr, Nieman L., Chrousos G., Pass H., Doppman J. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991 Jun;15(6):529–553. doi: 10.1097/00000478-199106000-00003. [DOI] [PubMed] [Google Scholar]
  26. Walther M. M., Gnarra J. R., Elwood L., Xu H. J., Florence C., Anglard P., Hu S. X., King C., Trahan E., Hurley K. Loss of heterozygosity occurs centromeric to RB without associated abnormalities in the retinoblastoma gene in tumors from patients with metastatic renal cell carcinoma. J Urol. 1995 Jun;153(6):2050–2054. [PubMed] [Google Scholar]
  27. Warren W. H., Faber L. P., Gould V. E. Neuroendocrine neoplasms of the lung. A clinicopathologic update. J Thorac Cardiovasc Surg. 1989 Sep;98(3):321–332. [PubMed] [Google Scholar]
  28. Xu H. J., Cagle P. T., Hu S. X., Li J., Benedict W. F. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res. 1996 Jul;2(7):1169–1176. [PubMed] [Google Scholar]
  29. Xu H. J., Cairns P., Hu S. X., Knowles M. A., Benedict W. F. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer. 1993 Mar 12;53(5):781–784. doi: 10.1002/ijc.2910530513. [DOI] [PubMed] [Google Scholar]
  30. Xu H. J., Hu S. X., Benedict W. F. Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene. 1991 Jul;6(7):1139–1146. [PubMed] [Google Scholar]
  31. Xu H. J., Hu S. X., Cagle P. T., Moore G. E., Benedict W. F. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res. 1991 May 15;51(10):2735–2739. [PubMed] [Google Scholar]
  32. Xu H. J., Hu S. X., Hashimoto T., Takahashi R., Benedict W. F. The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells. Oncogene. 1989 Jun;4(6):807–812. [PubMed] [Google Scholar]
  33. Xu H. J., Quinlan D. C., Davidson A. G., Hu S. X., Summers C. L., Li J., Benedict W. F. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 1994 May 4;86(9):695–699. doi: 10.1093/jnci/86.9.695. [DOI] [PubMed] [Google Scholar]
  34. Zhang X., Xu H. J., Murakami Y., Sachse R., Yashima K., Hirohashi S., Hu S. X., Benedict W. F., Sekiya T. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res. 1994 Aug 1;54(15):4177–4182. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES